Founded in 2009 by Brian Pierce & Larry Zluch, Photometics’ vision is to continually advance cancer therapeutics through the use of light‐based technologies to effectively disrupt cancer cells without dangerous drugs and without affecting healthy tissue.
At a young age, Brian’s life was forever changed as he watched both of his parents struggle with the horrible side effects of cancer treatment. Out of their pain, his life’s motivation to cure cancer without the awful side effects of traditional treatments was born.
Early in his career, Brian successfully developed a sterilization method for produce using infrared light to target unique wavelengths. He saw the opportunity to apply this use of infrared light to trigger Selective Photo-Apoptosis on cancer. Brian continued to advance the technology up to his passing in 2018 when he succumbed to his own battle with cancer.
Photometics is committed to carrying Brian’s vision through the widespread application of his groundbreaking technology.
Photometics’ patented cancer therapy promises painless, non-invasive treatments with no scarring or toxic reactions in healthy surrounding tissue. Photometics’ state-of-the-art, patented, femtosecond laser technology delivers extremely high power pulses, selectively to cancer cells, causing them to disintegrate
Lung cancer cells dividing
Treatment applications extend well beyond basal cell skin cancer and research is being planned to test the efficacy on other types of cancer.
Brian’s earlier technology is currently in market successfully treating human pathogens (fungus and bacteria of the foot) under license to NuvoLase.
Additional uses are being considered in aesthetics, R&D, Industrial and Military applications.